logo
Parents face hurdles vaccinating children

Parents face hurdles vaccinating children

Yahoo20 hours ago
Parents are being prevented from vaccinating their children because of obstacles such as difficulty booking appointments and a lack of reminders on what jabs are needed and when, a report suggests.
Child health experts say "practical or logistical reasons" are discouraging families more often than fears over the vaccines.
Vaccine uptake in the UK has fallen over the last decade, leading to outbreaks of measles and whooping cough.
UK health officials say they are committed to working with the NHS to improve vaccine uptake among children.
Since 2022, no childhood vaccine in the UK has met the World Health Organisation target of 95% of children vaccinated, which ensures protection of vulnerable people. As a result, measles and other preventable diseases have made a comeback.
A commission of experts from the Royal College of Paediatrics and Child Health (RCPCH) spent a year looking at why.
Dr Helen Stewart, officer for health improvement at RCPCH, said the steady decline in vaccination rates in a wealthy country like the UK was "extremely concerning".
But she said vaccine hesitancy, when parents waver over getting their children vaccinated, "is only part of a very complex picture".
"The reality is that there are many who simply need better support and easier access to appointments," Dr Stewart said.
Although confidence in vaccines is still relatively high, the report found barriers to accessing jabs are why many families don't protect their children.
Some of the most common barriers include:
difficulties getting through to book appointments at GP surgeries
difficulties getting time off work for appointments
limited transport options or no parking at GP surgeries
not seeing the same GP each time so lack of trust
not being able to speak to a GP or nurse to ask about the vaccines
lack of reminders for jabs being sent out from GP
not enough clear information about what jabs their child needs and when
"One of the findings of this new report is that parents have no easy way to check their child's vaccination status," says children's emergency medicine specialist, Dr Stewart.
"When I ask if the child is up to date with their vaccinations, the most common response is 'I think so'."
Poorer families, some ethnic minority groups and migrant communities are much less likely to be vaccinated, and these inequalities have become more obvious since the pandemic, the report says.
It also notes an absence of health visitors often means parents have no one they feel comfortable discussing vaccines openly with.
Rise of vaccine distrust - why more of us are questioning jabs
The report recommends using NHS apps to improve the experience of booking jabs, investing and expanding vaccination services, and funding health visitors to deliver some of them.
It also calls on the development of the 'digital red book' to be finalised so parents can keep track of their children's vaccinations.
The NHS website lists the full schedule of vaccinations for children, from babies, up to the age of 15.
Dr Julie Yates, deputy director for immunisation programmes at UK Health Security Agency, said plans were in place to improve childhood vaccine uptake by ensuring more flexible appointment booking systems, making vaccines more widely available across different locations, and making access easier in all communities.
"Despite the challenges, it is also important to note that parents have high confidence in vaccinations with almost 90% agreeing vaccines are effective," Dr Yates said.
Alison Morton, chief executive of the Institute for Health Visitors, said the report presented "a compelling case" to ensure babies and children are protected against serious diseases which can cause so much unnecessary harm.
Helen Bedford, professor of children's health at University College London, said improvements needed investment in staff and infrastructure.
"Our children have the right to be protected from preventable diseases which can cause illness, disability or even death," she said, adding that a fall in children getting their vaccines had resulted in the deaths of 11 young babies from whooping cough last year.
Falling vaccinations among children isn't just an issue in the UK, in 2023 there were nearly 16 million children who had not had any vaccinations, most of them in south Asia and sub-Saharan Africa.
Vaccination plea after measles cases rise in Scotland
Millions of children at risk as vaccine uptake stalls
Measles highest in 25 years in Europe, WHO says
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

All Illinois children will have to be tested for lead exposure in 2026
All Illinois children will have to be tested for lead exposure in 2026

CBS News

time44 minutes ago

  • CBS News

All Illinois children will have to be tested for lead exposure in 2026

By this time next year, all children in Illinois will have lead exposure testing as the state expands the zip codes considered high risk. The state is adding 180 more zip codes where led exposure testing will be required, part of a push for universal statewide lead exposure testing. Under state law, every child must be tested for lead exposure at 1 and 2 years old starting in 2026. All kids aged 6 and younger must also be asked about exposure by a health care provider. The expansion comes as Cook County home health care service Lead Care celebrated replacing 200 lead service lines in the county for free, giving hundreds of childcare facilities in the suburbs access to safe drinking water. Cook County communities have some of the highest number of lead service lines in the U.S. Lead exposure poses a serious health risk to children under 6.

CISH-Targeted TILs Show Promise in GI Cancer Trial
CISH-Targeted TILs Show Promise in GI Cancer Trial

Medscape

timean hour ago

  • Medscape

CISH-Targeted TILs Show Promise in GI Cancer Trial

This transcript has been edited for clarity. Hello. I'm David Kerr, professor of cancer medicine at University of Oxford. I'd like to talk a little about a phase 1 trial that has just been published in the May edition of Lancet Oncology , a beautiful paper by Emil Lou and colleagues, in which they all looked at an extraordinarily complicated regimen of gene editing and then reinfusing tumor-infiltrating lymphocytes (TILs). This just shows how remarkable modern cancer medicine can be. I'd like to talk a little about the procedures involved, given the route of complexity. Initially, for patients in the phase 1 trial with metastatic advanced gastrointestinal cancer, the first step was to receive a non-myeloablative lymphocyte-depletion chemotherapy. This is cyclophosphamide and fludarabine. This is then followed by high-dose interleukin-2. The process of producing the gene-edited TILs is absolutely fascinating. The gene-editing target, the gene that we wanted to knock down, was a novel, internal immune checkpoint protein gene, CISH , which encoded a cytokine-inducible SH2 domain-containing protein. This is an internal immune checkpoint target and quite an interestingly novel one. That's the target to knock down. The process of building the therapy is completely fascinating. Autologous TILs were generated from tumor biopsy fragments from each individual patient, and samples of the TILs were then cultured with patient-derived lymphoblastic cell lines, ormonocyte-derived dendritic cells loaded with pools of synthetic 25-mer peptides containing tumor-specific mutations that were detected from whole-exome sequencing from the patient's tumor. Think about that for a second. The patients undergo biopsy. The TILs are taken off for culture — more on that later — but they were co-cultured with a source of patient-specific tumor-associated antigens, which were generated by whole-exome sequencing. Then, using 25-mer fragments of what they felt were the key tumor-specific antigens, were plumbed into the patients' own dendritic cells so that these antigens would be presented to at the time of co-culture with a patient, so in TILs. It boggles the mind. The TILs with demonstrated reactivity to the neoantigens in this co-culture experiment were selected and they were then subjected to the CRISPR gene editing in vitro. They knocked down CISH , the target that they were aiming for. Then the edited TILs underwent a rapid expansion protocol. They were cryopreserved, and then via some very sophisticated molecular quality control, infused back into the patients. Goodness gracious — I mean, it's extraordinary when you think about it. It was a phase 1 trial, so dose-escalating the number of cells. It's pretty well tolerated. As you would expect, there was some fatigue and some fever. Nobody died in the back of any of the treatment that was given in that way. In terms of effectiveness, these were patients with advanced disease who had undergone multiple previous lines of treatment. There were no severe cytokine-release syndromes, nothing of grade 3 or worse. No neurotoxicity. Six of 12 patients had stable disease by day 28. Four (33%) had stable disease ongoing at 56 days. One young adult who had microsatellite-unstable and mismatch repair-deficient MSI-high tumors — therefore they've already got an existing high neoantigen load — had a complete response. That was very pleasing. I say, again, this is an extraordinary piece of work, to think about the complexity involved in every step of that process — before the patients' own cells, the autologous cells, were manipulated and reinfused with moderately acceptable toxicity, I would say. It's a phase 1 trial, so you're not really looking for a big efficacy readout, but the one younger patient who had, if you like, a genetic predisposition to responding to immunotherapy anyway, had a complete response. I'd be really interested in what you think about it. Who knows what the cost of that would be in terms of the complexity — I keep using that word, don't I? — of every single step. Modern cancer medicine — don't you love it? Well done to the team for producing this phase 1 trial result. How generalizable it will be remains to be seen, given the multiple different steps that are required. It just shows you how, in my lifetime as a cancer doctor, four decades, remarkable progress has been. I'm very interested in any comments you'd have to make. As always, thanks for listening. For the time being, Medscapers, ahoy, and over and out.

AstraZeneca may quit London stock market
AstraZeneca may quit London stock market

Yahoo

time2 hours ago

  • Yahoo

AstraZeneca may quit London stock market

AstraZeneca's chief executive has discussed shifting the company's stock market listing to the US in a move that would deal a huge blow to London. Sir Pascal Soriot has reportedly spoken of his desire to move the listing to the US in private meetings and suggested moving AstraZeneca's domicile away from the UK. Shares jumped almost 3pc following the report in The Times, which indicates that investors support the idea. AstraZeneca leaving would be a huge blow to the London Stock Exchange, which has been reeling from a string of departures and a dearth of new listings. It would also be a setback for the Government, which is expected to unveil its long-awaited life sciences sector plan within days. AstraZeneca is the largest listed business in London and Britain's biggest drugmaker, with its headquarters in Cambridge. Sir Pascal has been increasingly critical of red tape in the UK and the charges paid by drugmakers to the NHS. Last year, pharmaceutical companies paid the NHS £3bn under a drug rebate scheme meant to stop the health service's costs spiralling out of control. However, the cost of the scheme to drugmakers has ballooned since the pandemic. Sir Pascal has been among those to criticise the scheme, telling the Government that it should 'continue working on improving the environment to attract investment'. AstraZeneca has snubbed the UK for investment in recent years amid concerns over the operating environment. In 2023, it said it had overlooked Britain for a new $400m (£320m) drug factory because of its 'discouraging' tax regime. Last year, AstraZeneca axed plans for a separate £450m vaccine factory in Liverpool after the Government lowered the financial support available. Speaking in April, Sir Pascal said investment would go towards countries that favour AstraZeneca by buying its cutting-edge medicines. He said: 'Companies will follow where they feel welcome. In our industry, it's a question of where do we think patients will be able to benefit from our products and we invest there.' The prospect of AstraZeneca quitting the London market and shifting its headquarters will pile pressure on ministers to improve the UK for drug companies. Labour is this week expected to outline its strategy to turn Britain into the world's third-largest pharma superpower after the US and China. The strategy has already been hit by setbacks, with ministers last week scrambling to agree a crucial deal on NHS drug charges that was meant to be at the centre of its plan to boost growth. AstraZeneca's exit would also ramp up pressure on the London Stock Exchange, which has been hit by a raft of high-profile exits, including Paddy Power owner Flutter and drugs giant Indivior. Any move by AstraZeneca would require board approval. The company declined to comment. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store